Vaxart, Inc., a San Francisco, CA-based biotechnology company developing oral-delivery vaccines, has closed a $12.5m Series B financing.
The round was led by Care Capital of Princeton NJ.
The funding will be used to advance the company’s lead product, an oral vaccine for Avian influenza, through Phase I clinical trials.
The vaccines incorporate a proprietary adjuvant, which boosts the immune response, enabling a vaccine to be effective when swallowed in a pill or capsule.
As part of the financing, Richard Markham and Jan Leschly of Care Capital have joined Vaxart’s board.